PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Chymotrypsin→

Chymotrypsin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
9004-07-3
Molecular formula
Not available
Molecular weight
Not available
Drug class
Proteolytic enzymeserine endopeptidase
Mechanism of action
Hydrolyses peptide bonds adjacent to aromatic amino acids, including phenylalanine, tyrosine and tryptophan. Pharmaceutical preparations are used for local or systemic proteolytic effects depending on formulation.
Indications / reported uses
  • Used in selected countries as an enzyme preparation for reduction of local oedema or as an adjunct in wound-care or ophthalmic procedures; clinical indications and evidence depend on the specific formulation and route

Sources: NLM MeSH — Chymotrypsin · PubMed — Chymotrypsin therapeutic preparations · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Chymotrypsin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Chymotrypsin Permitted Daily Exposure (PDE) report (the Chymotrypsin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Chymotrypsin Occupational Exposure Limit (OEL) report (the Chymotrypsin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.